{"id":20024,"date":"2020-02-07T10:50:36","date_gmt":"2020-02-07T09:50:36","guid":{"rendered":"https:\/\/2020.ddz.de\/?p=20024"},"modified":"2020-02-10T11:59:48","modified_gmt":"2020-02-10T10:59:48","slug":"neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes","status":"publish","type":"post","link":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/","title":{"rendered":"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes"},"content":{"rendered":"\n<p>Das f\u00fcr eine Laufzeit von drei Jahren gef\u00f6rderte Forschungsprojekt zielt darauf ab, in einer pr\u00e4klinischen Stufe eine neue Klasse von Peptiden zu entwickeln. Diese sollen \u00fcber einen spezifischen Signalweg die Insulinsekretion ausl\u00f6sen und gleichzeitig pankreatische Betazellen sch\u00fctzen und die Instabilit\u00e4t atherosklerotischer Plaques verhindern. \u201eMit Hilfe von In-vitro-Studien werden wir die Wirkungsmechanismen ausgew\u00e4hlter Peptide untersuchen und die Signalausl\u00f6sung in verschiedenen Zelltypen analysieren&#8221;, erkl\u00e4rt Prof. Dr. Michael Roden, Wissenschaftlicher Direktor und Vorstand des DDZ. \u201eEin hoch-innovatives Projekt, das am Ende der Laufzeit, so hoffen wir, ein neues Peptid hervorbringt, um die Therapie von Menschen mit Diabetes zu verbessern&#8221;, so Roden weiter.<\/p>\n\n\n\n<p>Das Verbundprojekt DIA-PEP zielt auf die pr\u00e4klinische Entwicklung einer neuen Klasse von Peptiden zur Therapie des Diabetes mellitus ab. Das Deutsche Diabetes-Zentrum (DDZ) arbeitet zusammen mit den Partnern: Follicum AB (Lund, Schweden), Lund University und Bioassay GmbH (Heidelberg). Das Forschungskooperationsprojekt wird im Rahmen von Eurostars, einem gemeinsamen F\u00f6rderprogramm von EUREKA und der Europ\u00e4ischen Kommission, unterst\u00fctzt. Die Projektf\u00f6rderung erh\u00e4lt das Deutsche Diabetes-Zentrum vom BMBF.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter\"><img loading=\"lazy\" decoding=\"async\" width=\"180\" height=\"120\" src=\"https:\/\/ddz.de\/wp-content\/uploads\/BMBF-Logo_image_full_resize.jpg\" alt=\"\" class=\"wp-image-20032\"\/><\/figure><\/div>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"172\" src=\"https:\/\/ddz.de\/wp-content\/uploads\/eurostars_eureka_eu_logos-participants-1024x172.jpg\" alt=\"\" class=\"wp-image-20029\" srcset=\"https:\/\/ddz.de\/wp-content\/uploads\/eurostars_eureka_eu_logos-participants-1024x172.jpg 1024w, https:\/\/ddz.de\/wp-content\/uploads\/eurostars_eureka_eu_logos-participants-300x50.jpg 300w, https:\/\/ddz.de\/wp-content\/uploads\/eurostars_eureka_eu_logos-participants-768x129.jpg 768w, https:\/\/ddz.de\/wp-content\/uploads\/eurostars_eureka_eu_logos-participants.jpg 1554w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Das f\u00fcr eine Laufzeit von drei Jahren gef\u00f6rderte Forschungsprojekt zielt darauf ab, in einer pr\u00e4klinischen Stufe eine neue Klasse von Peptiden zu entwickeln. Diese sollen \u00fcber einen spezifischen Signalweg die [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":20025,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_FSMCFIC_featured_image_caption":"","_FSMCFIC_featured_image_nocaption":"","_FSMCFIC_featured_image_hide":"","footnotes":""},"categories":[38],"tags":[],"class_list":["post-20024","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressemitteilungen"],"acf":{"attachments":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes - Deutsches Diabetes-Zentrum (DDZ)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes - Deutsches Diabetes-Zentrum (DDZ)\" \/>\n<meta property=\"og:description\" content=\"Das f\u00fcr eine Laufzeit von drei Jahren gef\u00f6rderte Forschungsprojekt zielt darauf ab, in einer pr\u00e4klinischen Stufe eine neue Klasse von Peptiden zu entwickeln. Diese sollen \u00fcber einen spezifischen Signalweg die [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsches Diabetes-Zentrum (DDZ)\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/diabetesinformationsdienst\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-07T09:50:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-02-10T10:59:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Laura\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ddz_info\" \/>\n<meta name=\"twitter:site\" content=\"@ddz_info\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laura\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/\"},\"author\":{\"name\":\"Laura\",\"@id\":\"https:\/\/ddz.de\/en\/#\/schema\/person\/ccb99230dcdb9254fcf4b6863fece2d8\"},\"headline\":\"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes\",\"datePublished\":\"2020-02-07T09:50:36+00:00\",\"dateModified\":\"2020-02-10T10:59:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/\"},\"wordCount\":190,\"publisher\":{\"@id\":\"https:\/\/ddz.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg\",\"articleSection\":[\"Pressemitteilungen\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/\",\"url\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/\",\"name\":\"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes - Deutsches Diabetes-Zentrum (DDZ)\",\"isPartOf\":{\"@id\":\"https:\/\/ddz.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg\",\"datePublished\":\"2020-02-07T09:50:36+00:00\",\"dateModified\":\"2020-02-10T10:59:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage\",\"url\":\"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg\",\"contentUrl\":\"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg\",\"width\":800,\"height\":533,\"caption\":\"Wissenschaftler verwendet eine Pipette, um Fl\u00fcssigkeit in ein Reagenzglas in einem Labor zu \u00fcbertragen.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/ddz.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ddz.de\/en\/#website\",\"url\":\"https:\/\/ddz.de\/en\/\",\"name\":\"Deutsches Diabetes-Zentrum (DDZ)\",\"description\":\"Diabetes erforschen - Menschen helfen\",\"publisher\":{\"@id\":\"https:\/\/ddz.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ddz.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ddz.de\/en\/#organization\",\"name\":\"Deutsches Diabetes-Zentrum (DDZ)\",\"url\":\"https:\/\/ddz.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ddz.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ddz.de\/wp-content\/uploads\/ddz_logo_de.png\",\"contentUrl\":\"https:\/\/ddz.de\/wp-content\/uploads\/ddz_logo_de.png\",\"width\":640,\"height\":226,\"caption\":\"Deutsches Diabetes-Zentrum (DDZ)\"},\"image\":{\"@id\":\"https:\/\/ddz.de\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/diabetesinformationsdienst\/\",\"https:\/\/x.com\/ddz_info\",\"https:\/\/www.youtube.com\/channel\/UCNxwshEljrBJXPri-w9IiLg\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/ddz.de\/en\/#\/schema\/person\/ccb99230dcdb9254fcf4b6863fece2d8\",\"name\":\"Laura\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/26bdb2675e6cefd49caea545aa51bacafea136c3d55678e5e6da6c1133bda76f?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/26bdb2675e6cefd49caea545aa51bacafea136c3d55678e5e6da6c1133bda76f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/26bdb2675e6cefd49caea545aa51bacafea136c3d55678e5e6da6c1133bda76f?s=96&d=mm&r=g\",\"caption\":\"Laura\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes - Deutsches Diabetes-Zentrum (DDZ)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes - Deutsches Diabetes-Zentrum (DDZ)","og_description":"Das f\u00fcr eine Laufzeit von drei Jahren gef\u00f6rderte Forschungsprojekt zielt darauf ab, in einer pr\u00e4klinischen Stufe eine neue Klasse von Peptiden zu entwickeln. Diese sollen \u00fcber einen spezifischen Signalweg die [&hellip;]","og_url":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/","og_site_name":"Deutsches Diabetes-Zentrum (DDZ)","article_publisher":"https:\/\/www.facebook.com\/diabetesinformationsdienst\/","article_published_time":"2020-02-07T09:50:36+00:00","article_modified_time":"2020-02-10T10:59:48+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg","type":"image\/jpeg"}],"author":"Laura","twitter_card":"summary_large_image","twitter_creator":"@ddz_info","twitter_site":"@ddz_info","twitter_misc":{"Written by":"Laura","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#article","isPartOf":{"@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/"},"author":{"name":"Laura","@id":"https:\/\/ddz.de\/en\/#\/schema\/person\/ccb99230dcdb9254fcf4b6863fece2d8"},"headline":"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes","datePublished":"2020-02-07T09:50:36+00:00","dateModified":"2020-02-10T10:59:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/"},"wordCount":190,"publisher":{"@id":"https:\/\/ddz.de\/en\/#organization"},"image":{"@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg","articleSection":["Pressemitteilungen"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/","url":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/","name":"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes - Deutsches Diabetes-Zentrum (DDZ)","isPartOf":{"@id":"https:\/\/ddz.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg","datePublished":"2020-02-07T09:50:36+00:00","dateModified":"2020-02-10T10:59:48+00:00","breadcrumb":{"@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#primaryimage","url":"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg","contentUrl":"https:\/\/ddz.de\/wp-content\/uploads\/AdobeStock_243507812-e1581328469651.jpeg","width":800,"height":533,"caption":"Wissenschaftler verwendet eine Pipette, um Fl\u00fcssigkeit in ein Reagenzglas in einem Labor zu \u00fcbertragen."},{"@type":"BreadcrumbList","@id":"https:\/\/ddz.de\/en\/neue-eu-forschungskooperation-am-ddz-praeklinische-entwicklung-neuartiger-peptide-zur-therapie-des-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/ddz.de\/en\/"},{"@type":"ListItem","position":2,"name":"Neue EU-Forschungskooperation am DDZ: Pr\u00e4klinische Entwicklung neuartiger Peptide zur Therapie des Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/ddz.de\/en\/#website","url":"https:\/\/ddz.de\/en\/","name":"Deutsches Diabetes-Zentrum (DDZ)","description":"Diabetes erforschen - Menschen helfen","publisher":{"@id":"https:\/\/ddz.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ddz.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ddz.de\/en\/#organization","name":"Deutsches Diabetes-Zentrum (DDZ)","url":"https:\/\/ddz.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ddz.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ddz.de\/wp-content\/uploads\/ddz_logo_de.png","contentUrl":"https:\/\/ddz.de\/wp-content\/uploads\/ddz_logo_de.png","width":640,"height":226,"caption":"Deutsches Diabetes-Zentrum (DDZ)"},"image":{"@id":"https:\/\/ddz.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/diabetesinformationsdienst\/","https:\/\/x.com\/ddz_info","https:\/\/www.youtube.com\/channel\/UCNxwshEljrBJXPri-w9IiLg"]},{"@type":"Person","@id":"https:\/\/ddz.de\/en\/#\/schema\/person\/ccb99230dcdb9254fcf4b6863fece2d8","name":"Laura","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/26bdb2675e6cefd49caea545aa51bacafea136c3d55678e5e6da6c1133bda76f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/26bdb2675e6cefd49caea545aa51bacafea136c3d55678e5e6da6c1133bda76f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/26bdb2675e6cefd49caea545aa51bacafea136c3d55678e5e6da6c1133bda76f?s=96&d=mm&r=g","caption":"Laura"}}]}},"_links":{"self":[{"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/posts\/20024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/comments?post=20024"}],"version-history":[{"count":2,"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/posts\/20024\/revisions"}],"predecessor-version":[{"id":20034,"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/posts\/20024\/revisions\/20034"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/media\/20025"}],"wp:attachment":[{"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/media?parent=20024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/categories?post=20024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ddz.de\/en\/wp-json\/wp\/v2\/tags?post=20024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}